Skip to main content
SpringerLink
Log in

Antimicrobial Agents, Drug Adverse Reactions and Interactions, and Cancer

  • Chapter
  • First Online:
Infectious Complications in Cancer Patients

Part of the book series: Cancer Treatment and Research ((CTAR,volume 161))

Abstract

The intent of this chapter is to review the types of adverse drug reactions and interactions associated with antimicrobial agents, specifically in the setting of patients with malignancies. The initial sections will discuss categorizing and describing the mechanisms of adverse reactions and interactions. The later sections include a detailed discussion about adverse reactions and drug interactions associated with commonly used antibacterial, antiviral, and antifungal agents in this subpopulation. Where relevant, the clinical use and indication for the drugs will be reviewed. The antibacterial section will specifically address the emergence of antimicrobial resistance and drugs of last resort (newer agents, such as linezolid and daptomycin and novel uses of older previously retired agents, such as polymyxin B). The antifungal section will address the ramification of pharmacokinetic interactions and the need to measure drug levels. The chapter is not meant to be exhaustive and as such will not extensively address all antimicrobials or all interactions for each of these agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Freifeld A et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93. On-line at: http://www.idsociety.org/Antimicrobial_Agents/#Neutropenic%20Patients%20with%20Cancer. Last accessed on 12 Mar 2013

  2. Roder BL, Nielsen SL, Magnussen P, Engquist A, Frimodt-Moller N (1993) Antibiotic usage in an intensive care unit in a Danish university hospital. J Antimicrob Chemother 32:633–642

    Article  PubMed  CAS  Google Scholar 

  3. Lazarou J et al (1998) Incidence of adverse drug reactions in hospitalized patients: a meta analysis of prospective studies. JAMA 279:1200–1205

    Article  PubMed  CAS  Google Scholar 

  4. Nebeker JR, Barach P, Samore M (2004) Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med 140:795–801

    Google Scholar 

  5. Riedl M, Casillas A (2003) Adverse drug reactions: types and treatment options. Am Fam Physician 68(9):1781–1791

    PubMed  Google Scholar 

  6. Gallicano K, Drusano G (2005) Introduction to drug interactions. In: Piscitelli S, Rodvold K (eds) Drug interactions in infectious diseases, 2nd edn. Humana Press, Totowa, pp 1–11

    Google Scholar 

  7. Executive summary of disease management of drug hypersensitivity: a practice parameter. Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology (1999). Ann Allergy Asthma Immunol 83:665–700

    Google Scholar 

  8. deShazo RD, Kemp SF (1997) Allergic reactions to drugs and biologic agents. JAMA 278:1895–1906

    Google Scholar 

  9. Anderson JA, Adkinson NF Jr (1987) Allergic reactions to drugs and biologic agents. JAMA 258:2891–2899

    Article  PubMed  CAS  Google Scholar 

  10. Granowitz E, Brown R (2008) Antibiotic adverse reactions and drug reactions. Crit Care Clin 24:421–442

    Article  PubMed  CAS  Google Scholar 

  11. Gunderson BW et al (2001) What do we really know about antibiotic pharmacodynamics? Pharmacotherapy 21(11s):302s–318s

    Article  PubMed  CAS  Google Scholar 

  12. Rodvold KA (2001) Pharmacodynamics of antiinfective therapy: taking what we know to the patient’s bedside. Pharmacotherapy 21(11 Pt 2):319S–330S

    Article  PubMed  CAS  Google Scholar 

  13. Guay D (2005) Quinlones. In: Piscitelli S, Rodvold K (eds) Drug interactions in infectious diseases, 2nd edn. Humana Press, Totowa, pp 215–244

    Google Scholar 

  14. Neuhauser M, Danziger L (2005) β-lactam antibiotics. In: Piscitelli S, Rodvold K (eds) Drug interactions in infectious diseases, 2nd edn. Humana Press, Totowa, pp 255–288

    Google Scholar 

  15. Susla G (2005) Miscellaneous antibiotics. In: Piscitelli S, Rodvold K (eds) Drug interactions in infectious diseases, 2nd edn. Humana Press, Totowa, pp 332–389

    Google Scholar 

  16. Rybak M, Rotschafer J, Moellering R et al (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm 66(1):82–98

    Article  PubMed  CAS  Google Scholar 

  17. Shoemaker M, Simou J, Roland W (2006) A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections. Ther Clin Risk Manag 2(2):169–174

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  18. Spratt BG, Cromie KD (1988) Penicillin-binding proteins of gram negative bacteria. Rev Infect Di s 10:699–711

    Article  CAS  Google Scholar 

  19. Pichichero ME (2007) Use of selected cephalosporins in pencillin-allergic patients—a paradigm shift. Diag Microbiol Infect Dis 57:13S–18S

    Article  CAS  Google Scholar 

  20. Saxon A et al (1984) Lack of cross-reactivity between aztreonam, a monobactam antibiotic, and penicillin in penicillin-allergic subjects. J Infect Dis 149(1):16–22

    Article  PubMed  CAS  Google Scholar 

  21. Lee CE, Zembower TR, Fotis MA et al (2000) The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch Intern Med 160:2819

    Article  PubMed  CAS  Google Scholar 

  22. Park M, Markus P, Matesic D, Li JT (2006) Safety and effectiveness of a preoperative allergy clinic in decreasing vancomycin use in patients with a history of penicillin allergy. Ann Allergy Asthma Immunol 97:681

    Article  PubMed  CAS  Google Scholar 

  23. Castells M (2009) Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin North Am 29(3):585–606

    Article  PubMed  Google Scholar 

  24. Kim A, Sutherland CA, Kuti JL, Nicolau DP (2007) Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy 27(11):1490–1497

    Google Scholar 

  25. Lodise TP Jr, Lomaestro B, Drusano GL (2007) Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 44(3):357–363

    Article  PubMed  CAS  Google Scholar 

  26. Adam O, Auperin A, Wilquin F, Bourhis JH, Gachot B, Chachaty E (2004) Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 38:917–920

    Article  PubMed  Google Scholar 

  27. Ansorg R, van den Boom R, Rath P (1997) Detection of Aspergillus galactomannan antigen in foods and antibiotics. Mycoses 40:353–357

    Article  PubMed  CAS  Google Scholar 

  28. Singh N et al. (2004) Reactivity of platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum. AAC 48:1989–1992. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC415629/

    Google Scholar 

  29. Yahav D, Paul M, Fraser A et al (2007) Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 7:338–348

    Article  PubMed  CAS  Google Scholar 

  30. Leibovici L, Yahav D, Paul M (2010) Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 51:1350–1351

    Article  PubMed  Google Scholar 

  31. Kim PW et al (2010) Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 51(4):381–389

    Article  PubMed  Google Scholar 

  32. Fisher BT, Aplenc R, Localio R, Leckerman KH, Zaoutis TE (2009) Cefepime and mortality in pediatric acute myelogenous leukemia: a retrospective cohort study. Pediatr Infect Dis J 28(11):971–975

    Article  PubMed  Google Scholar 

  33. FDA (2007) Cefepime (marketed as Maxipime). Update of ongoing safety review. Updated May 2008

    Google Scholar 

  34. Zhanel GG et al (2007) Comparative review of the carbapenems. Drugs 67(7):1027–1052

    Article  PubMed  CAS  Google Scholar 

  35. Paterson DL, Depestel DD (2009) Doripenem. Clin Infect Dis 49(2):291–298

    Article  PubMed  CAS  Google Scholar 

  36. Asbel LE, Levison ME (200) Caphalosporins, carbapenems and monbactams. Infect Dis Clin North Am 14:435–447

    Google Scholar 

  37. CDC (2009) Guidance for control of infections with carbapenem-resistant or carbepenemase—producing Enterobacteriacea in acute care facilities. MMWR 58 (10):256–260

    Google Scholar 

  38. Wolfson JS, Hooper DC (1989) Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 2(4):378–442

    PubMed Central  PubMed  CAS  Google Scholar 

  39. Lipsky BA, Baker CA (1999) Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 28(2):352

    Article  PubMed  CAS  Google Scholar 

  40. Meyer RD (1986) Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides. Am J Med 80:119

    Article  PubMed  CAS  Google Scholar 

  41. Hooper DC (1999) Mechanisms of fluoroquinolone resistance. Drug Resist Updat 2(1):38

    Article  PubMed  CAS  Google Scholar 

  42. Neuhauser MM (2003) Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289(7):885

    Article  PubMed  CAS  Google Scholar 

  43. Mcdonald CL et al (2005) An epidemic, toxin gene–variant strain of Clostridium difficile. N Engl J Med 353:2433–2441

    Article  PubMed  CAS  Google Scholar 

  44. Kumana CR, Yuen KY (1994) Parenteral aminoglycoside therapy. Selection, administration and monitoring. Drugs 47:902–913

    Article  PubMed  CAS  Google Scholar 

  45. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM (1999) Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 43:727–737

    PubMed Central  PubMed  CAS  Google Scholar 

  46. Fantin B, Ebert S, Leggett J et al (1991) Factors affecting duration of in vivo postantibiotic effect for aminoglycosides against gram-negative bacilli. J Antimicrob Chemother 27:829–836

    Article  PubMed  CAS  Google Scholar 

  47. Humes HD (1988) Aminoglycoside nephrotoxicity. Kidney Int 33:900

    Article  PubMed  CAS  Google Scholar 

  48. Moore RD, Smith CR, Lipsky JJ et al (1984) Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 100:352

    Article  PubMed  CAS  Google Scholar 

  49. Aronson JK, Reynolds DJ (1992) ABC of monitoring drug therapy. Aminoglycoside antibiotics. BMJ 305(6866):1421

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  50. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH (1997) Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 39(6):677

    Article  PubMed  CAS  Google Scholar 

  51. Munckhof WJ, Grayson ML, Turnidge JD (1996) A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 37:645

    Article  PubMed  CAS  Google Scholar 

  52. Ferriols-Lisart R, Alós-Almiñana M (1996) Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 53:1141

    PubMed  CAS  Google Scholar 

  53. Dobie RA, Black FO, Pezsnecker SC, Stallings VL (2006) Hearing loss in patients with vestibulotoxic reactions to gentamicin therapy. Arch Otolaryngol Head Neck Surg 132(3):253

    Article  PubMed  Google Scholar 

  54. Polk RE, Healy DP, Schwartz LB et al (1988) Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. J Infect Dis 157:502

    Article  PubMed  CAS  Google Scholar 

  55. Bailie GR, Neal D (1988) Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp 3:376

    Article  PubMed  CAS  Google Scholar 

  56. Moellering RC (2006) Vancomycin: a 50 year reassessment. Clin Infect Dis 42(suppl 1):S3–S4

    Article  PubMed  Google Scholar 

  57. Healy DP, Sahai JV, Fuller SH, Polk RE (1990) Vancomycin-induced histamine release and “red man syndrome”: comparison of 1- and 2-hour infusions. Antimicrob Agents Chemother 34:550

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  58. Anne S, Middleton E Jr, Reisman RE (1994) Vancomycin anaphylaxis and successful desensitization. Ann Allergy 73:402

    PubMed  CAS  Google Scholar 

  59. Moellering R (2003) Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 138:135–142

    Article  PubMed  CAS  Google Scholar 

  60. Sakoulas G, Moise-Broder PA, Schentag J et al (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398–2402

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  61. Hidayat LK, Hsu DI, Quist R et al (2006) High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166:2138–2144

    Article  PubMed  Google Scholar 

  62. Plosker G, Figgitt D (2005) Linezolid: a pharmcoeconomic review of its use in serious gram positive infections. Pharmcoeconomics 23(9):945–964

    Article  Google Scholar 

  63. Kainer M et al (2007) Response to emerging infection leading to outbreak of linezolid-resistant enterococci. EID 13(7):1024–1030

    CAS  Google Scholar 

  64. Perry CM, Jarvis B (2001) Linezolid: a review if its use in the management of serious gram—positive infections. Drugs 61(4):525–531

    Article  PubMed  CAS  Google Scholar 

  65. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH (2003) Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789–1797

    PubMed  CAS  Google Scholar 

  66. ATS/IDSA (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388–416

    Google Scholar 

  67. Shoemaker D, Simou J, Roland W (2006) A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure. Ther Clin Risk Manag 2(2):169–174

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  68. Cubicin package insert (2008) Cubist Pharmaceuticals Inc, Lexington

    Google Scholar 

  69. Rose W, Rybak W, Kaatz G (2007) Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. Antimicrob Chemother 60(2):334–340

    Article  CAS  Google Scholar 

  70. Oleson FB, Berman CL, Kirkpatrick JB et al (2000) Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 44:2948–2953

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  71. Wenzel R, Bate G, Kirkpatrick P (2005) Fresh from the pipeline: tigecycline. Nat Rev Drug Discov 4:809–810

    Google Scholar 

  72. Greer N (2006) Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent) 19(2):155–161

    Google Scholar 

  73. Hung WY et al (2009) Tigecycline-induced acute pancreatitis: case report and literature review. Int J Antimicrob Agents 34(5):486–489

    Google Scholar 

  74. U.S. Food and Drug Administration (2010) FDA drug safety communication: increased risk of death with tygacil (tigecycline) compared to other antibiotics used to treat similar infections, Safety announcement [09-01-2010] http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm. Last Accessed 12 Mar 2013

  75. Zavascki A, Goldani L, Nation R (2007) Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60(6):1206–1215

    Article  PubMed  CAS  Google Scholar 

  76. Evans ME, Feola DJ, Rapp RP (1999) Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 33:960–967

    Article  PubMed  CAS  Google Scholar 

  77. Falagas ME, Kasiakou SK (2006) Toxicity of polymyxins: a systematic review of the evidence fromold and recent studies. Crit Care 10:R27

    Article  PubMed Central  PubMed  Google Scholar 

  78. Higgins DL et al (2005) Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49(3):1127–1134

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  79. Stryjewski ME, Graham DR, Wilson SE et al (2008) Assessment of telavancin in complicated skin and skin-structure infections study. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 46(11):1683–1693

    Article  PubMed  CAS  Google Scholar 

  80. Wilson SE, O’Riordan W, Hopkins A (2009) Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. Am J Surg 197(6):791–796 (Epub 2008 Dec 18)

    Article  PubMed  CAS  Google Scholar 

  81. Dunbar L, Tang D, Manausa M (2008) A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI). Ther Clin Risk Manag 4(1):235–244

    PubMed Central  PubMed  CAS  Google Scholar 

  82. Daum RS (2008) Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 359:1063–1067

    Article  Google Scholar 

  83. Moellering R (2008) Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 46:1032–1037

    Article  PubMed  Google Scholar 

  84. Siberry G, Tekle T, Carroll K et al (2003) Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 37(9):1257–1260

    Article  PubMed  Google Scholar 

  85. Centers for Disease Control and Prevention (2000) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR Recomm Rep 49(RR-10):1–112. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4910a1.htm. Last accessed on 12 Mar 2013

  86. Diasio R (1998) Sorivudine and 5-fluorouracil; a clinically significant drug–drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br J Clin Pharmacol 46(1):1–4

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  87. Balfour H (1999) Antiviral drugs. N Engl J Med 340(16):1255–1268

    Article  PubMed  CAS  Google Scholar 

  88. Acyclovir for injection USP, package insert. Bedford laboratories (2013) http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Ben+Venue_Bedford+Labs/55390-612-10+ACY500MG/5539061210. Last accessed on 12 Mar 2013

  89. Mason J, Nickols H (2008) Crystalluria from acyclovir use. N Engl J Med 358(13):e14

    Article  PubMed  Google Scholar 

  90. Trifilio S, Verma A, Mehta J (2004) Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 33:735–739

    Article  PubMed  CAS  Google Scholar 

  91. Crumpaker C (1996) Ganciclovir. N Engl J Med 335(10):721–729

    Article  Google Scholar 

  92. Gooley T et al (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363:2091–2101

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  93. Holland GN (2008) AIDS and ophthalmology: the first quarter century. Am J Ophthalmol 145(3):397

    Article  PubMed  Google Scholar 

  94. Ganciclovir for infusion package insert (Cytovene). Roche Labs (2006, January) http://www.gene.com/gene/products/information/cytovene/pdf/pi.pdf. Last accessed on 12 Mar 2012

  95. Pescovitz MD, Rabkin J, Merion RM et al (2000) Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 44(10):2811–2815

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  96. Ljungman P, de La Camara R, Milpied N et al (2002) Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 99(8):3050–3056

    Article  PubMed  CAS  Google Scholar 

  97. Wagstaff A, Bryson H (1994) Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 48:199

    Article  PubMed  CAS  Google Scholar 

  98. Avery RK et al (2000) A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy. Bone Marrow Transplant 26:763–767

    Google Scholar 

  99. Cidofovir (Vistide®) package insert Gilead Sciences. http://www.gilead.com/pdf/vistide.pdf. Last accessed on 12 Mar 2013

  100. Vandercam B, Moreau M, Goffin E et al (1999) Cidofovir-induced end-stage renal failure. Clin Infect Dis 29:948

    Article  PubMed  CAS  Google Scholar 

  101. Meier P, Dautheville-Guibal S, Ronco PM, Rossert J (2002) Cidofovir-induced end-stage renal failure. Nephrol Dial Transplant 17:148

    Article  PubMed  Google Scholar 

  102. Vaccher E et al (2003) Improvement of systemic human immunodeficiency virus-related non hodgkin lymphoma in the era of highly active antiretrovial therapy. Clin Infect Dis 37:1556–1564

    Google Scholar 

  103. Jefferson T, Demicheli V, Rivetti D et al (2006) Antivirals for influenza in healthy adults: systematic review. Lancet 367:303

    Article  PubMed  CAS  Google Scholar 

  104. Cooper NJ, Sutton AJ, Abrams KR et al (2003) Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 326:1235

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  105. Hayden FG, Osterhaus AD, Treanor JJ et al (1997) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 337:874

    Article  PubMed  CAS  Google Scholar 

  106. Nichols WG, Guthrie KA, Corey L, Boeckh M (2004) Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 39:1300

    Article  PubMed  Google Scholar 

  107. Fiore AE, Fry A, Shay D et al (2011) Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Surveill Summ 60:1

    Google Scholar 

  108. Harper SA, Bradley JS, Englund JA et al (2009) Seasonal influenza in adults and children–diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 48:1003

    Article  PubMed  CAS  Google Scholar 

  109. Kiatboonsri S, Kiatboonsri C, Theerawit P (2010) Fatal respiratory events caused by zanamivir nebulization. Clin Infect Dis 50:620

    Article  PubMed  Google Scholar 

  110. Dominick L. Tamiflu (oseltamivir phosphate) Important Prescribing Information. Roche Pharmaceuticals. Revised 13 Nov 2006. http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM153422.pdf. Last accessed on 12 Mar 2013

  111. Marr KA, Patterson T, Denning D (2002) Aspergillosis: pathogenesis, clinical manifestations and therapy. Infect Dis Clin North Am 16:875–894

    Article  PubMed  Google Scholar 

  112. Marr KA, Carter RA, Boeckh M, Martin P, Corey L (2002) Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100:4358–4366

    Article  PubMed  CAS  Google Scholar 

  113. Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  114. Chamilos G, Luna M, Lewis RE et al (2006) Invasive fungal infections in patients with hematologic malignancies in a tertiary care center: an autopsy study over a 15-year period (1989–2003). Haematologica 91:986–989

    PubMed  Google Scholar 

  115. Roden MM, Zaoutis TE, Buchanan WL et al (2005) Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41:634–653

    Article  PubMed  Google Scholar 

  116. Nucci M, Silveira MI, Spector N et al (1998) Risk factors for death among cancer patients with fungemia. Clin Infect Dis 27:107–111

    Article  PubMed  CAS  Google Scholar 

  117. Carlson MA, Condon RE (1994) Nephrotoxicity of amphotericin B. J Am Coll Surg 179:361–381

    PubMed  CAS  Google Scholar 

  118. Walsh TJ et al (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46(3):327–360

    Article  PubMed  CAS  Google Scholar 

  119. Ellis D (2002) Amphotericin B: spectrum and resistance. J Antimicrob Chemother 49:7–10

    Google Scholar 

  120. Dupont B (2002) Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 49:31–36

    Article  PubMed  CAS  Google Scholar 

  121. Larkin J, Montero J (2003) Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med 20:201–206

    Google Scholar 

  122. Kuse ER, Chetchotisakd P, da Cunha CA et al (2007) Micafungin versus liposomal amphotericin B for candidemia and invasive candidosis: a phase III randomized double-blind trial. Lancet 369:1519–1527

    Article  PubMed  CAS  Google Scholar 

  123. Pappas PG, Kauffman CA, Andes D et al (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503–535

    Article  PubMed  CAS  Google Scholar 

  124. Wheat LJ, Freifeld AG, Kleiman MB et al (2007) Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 45:807–825

    Article  PubMed  Google Scholar 

  125. Fielding RM, Smith PC, Wang LH et al (1991) Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother 35:1208–1213

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  126. Boswell GW, Buell D, Bekersky I (1998) AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol 38:583–592

    Article  PubMed  CAS  Google Scholar 

  127. Bekersky I, Fielding RM, Dressler DE et al (2002) Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 46:828–833

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  128. Daneshmend TK, Warnock DW (1983) Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 8:17–42

    Article  PubMed  CAS  Google Scholar 

  129. Olsen SJ, Swedel MR, Blue B, Clark JM et al (1991) Tissue distribution of amphotericin B lipid complex in laboratory animals. J Pharmacol 43:831–835

    Article  CAS  Google Scholar 

  130. Atkinson A, Bennett J (1978) Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 13(2):271–276

    Article  PubMed Central  PubMed  Google Scholar 

  131. Nguyen MH, Peacock JE Jr, Morris AJ et al (1996) The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 100:617–623

    Article  PubMed  CAS  Google Scholar 

  132. Martins MD, Rex JH (1996) Resistance to antifungal agents in the critical care setting: problems and perspectives. New Horiz 4:338–344

    PubMed  CAS  Google Scholar 

  133. Yoon SA, Vazquez JA, Steffan PE et al (1999) High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob Agents Chemother 43:836–845

    PubMed Central  PubMed  CAS  Google Scholar 

  134. Dick JD, Merz WG, Saral R (1980) Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 18:158–163

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  135. Steinbach WJ, Perfect JR, Schell WA et al (2004) In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother 48:3217–3225

    Google Scholar 

  136. Wingard JR, White MH, Anaissie E, Raffalli J et al (2000) A randomized double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 31:1155–1163

    Article  PubMed  CAS  Google Scholar 

  137. Goodwin SD, Cleary JD, Walawander CA et al (1995) Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 20:755–761

    Article  PubMed  CAS  Google Scholar 

  138. Girois SB, Chapuis F, Decullier E et al (2006) Adverse effects of antifungal therapies in invasive fungal infections; review and meta-analysis. Eur J Clin Microbiol Infect Dis 25:138–149

    Article  PubMed  CAS  Google Scholar 

  139. Luber AD, Maa L, Lam M et al (1999) Risk factors for amphotercin B-induced nephrotoxicity. J Antimicrob Chemother 43:267–271

    Google Scholar 

  140. Deray G (2002) Amphotericin B nephrotoxicity. J Antimicrob Chemoter 49(Suppl 1):37–41

    Article  CAS  Google Scholar 

  141. Girois SB, Chapuis F, Decullier E et al (2006) Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis 25:138–149

    Article  PubMed  CAS  Google Scholar 

  142. Barrett JP, Vardulaki KA, Conlon C et al (2003) A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 23:1295–1320

    Article  Google Scholar 

  143. Walsh TJ, Finberg RW, Arndt C et al (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340:764–771

    Article  PubMed  CAS  Google Scholar 

  144. Gubbins P, McConnell S, Amsden J (2005) Antifungal agents. In: Piscitelli S, Rodvold K (eds) Drug interactions in infectious diseases, 2nd edn. Humana Press, Totowa, pp 289–337

    Google Scholar 

  145. Sporanox package insert (2004) Janssen Pharmaceutica, Titusville

    Google Scholar 

  146. Vfend package insert (2004) Roeirg, New York

    Google Scholar 

  147. Purkins L, Wood N, Ghahramani P et al (2003) Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety and toleration. Br J Clini Pharmacol 56(Suppl 1):37–44

    Article  CAS  Google Scholar 

  148. Krishna G, Parsons A, Kantesaria B et al (2007) Evaluation of pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin 23:545–552

    Article  PubMed  CAS  Google Scholar 

  149. Karthaus M, Cornely OA (2006) Second-line treatment in invasive mould infections. Mycoses 49(Suppl 1):23–26

    Article  PubMed  CAS  Google Scholar 

  150. Owens RC Jr, Nolin TD (2006) Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 43:1603–1611

    Article  PubMed  CAS  Google Scholar 

  151. McLachlan AJ, Tett ES (1996) Pharmacokinetics of fluconazole in people with HIV infection: a population analysis. Br J Clin Pharmacol 41:291–298

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  152. Pfaller MA, Diekema DJ, Sheehan DJ (2006) Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 19:435–447

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  153. Pai MP, Turpin RS, Garey KW et al (2007) Association of fluconazole area under concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 51:35–39

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  154. Baddley JW, Patel M, Bhavnani SM et al (2008) Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 52:3022–3028

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  155. Pfaller MA, Diekema DJ, Gibbs DL et al (2007) Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 45(6):1735–1745

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  156. Diaz M, Negroni R, Montero-Gei F et al (1992) A Pan-American 5-year study of fluconazole therapy for deep mycosis in the immunocompetent host. Pan-American Study Group. Clin Infect Dis 14(Suppl 1):S68–S76

    Article  PubMed  Google Scholar 

  157. Barone JA, Koh JG, Bierman RH et al (1993) Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 37:778–784

    Google Scholar 

  158. Prentince AG, Glasmacher A (2005) Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 56:17–22

    Article  CAS  Google Scholar 

  159. Hardin TC, Graybill JR, Fetchick R et al (1988) Pharmacokinetics of intraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 32:1310–1313

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  160. Persat F, Marzllo C, Guyotat D et al (1992) Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 45:838–841

    Article  Google Scholar 

  161. Cartledge JD, Midgely J, Gazzard BG (1997) Itraconazole solution: higher drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J Clin Pathol 50:477–480

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  162. Boogaerts MA, Verhoef GE, Zachee P et al (1989) Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 32(Suppl 1):103–108

    PubMed  Google Scholar 

  163. Potter M (2005) Strategies for managing systemic fungal infection and the place of itraconazole. J Antimicrob Chemoter 56 (Suppl 1): 149–154

    Google Scholar 

  164. Tucker RM, Haq Y, Denning DW et al (1990) Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 26:561–566

    Article  PubMed  CAS  Google Scholar 

  165. Ahmad SR, Singer SJ, Leissa BG (2001) Congestive heart failure associated with itraconazole. Lancet 357:1766–1767

    Article  PubMed  CAS  Google Scholar 

  166. Sharkey PK, Rinaldi MG, Dunn JF et al (1991) High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 35:707–713

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  167. Purkins L, Wood N, Ghahramani P et al (2002) Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob Agents Chemother 46:2546–2553

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  168. Purkins L, Wood N, Kleinermans D, Greenhalgh K et al (2003) Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 56(Suppl 1):17–23

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  169. Dening DW, Ribaud P, Milpied N et al (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571

    Article  Google Scholar 

  170. Shimizu T, Ochiai H, Asell F, Shimizu H et al (2003) Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CPY2C19. Drug Metab Pharmacokinet 18:48–70

    Article  PubMed  CAS  Google Scholar 

  171. Herbrecht R, Denning DW, Metry D (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415

    Article  PubMed  CAS  Google Scholar 

  172. Johnson LB, Kauffman CA (2003) Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36:630–637

    Article  PubMed  CAS  Google Scholar 

  173. Denning DW, Griffiths CEM (2001) Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 26:648–653

    Article  PubMed  CAS  Google Scholar 

  174. Ezzet F, Wexler D, Courtney R et al (2005) Oral bioavailability of posaconazole in fasted healthy subjects comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 44:211–220

    Article  PubMed  CAS  Google Scholar 

  175. Courtney R, Radwanski E, Lim J et al (2004) Pharmacokinetics of posaconazole co-administered with antacid in fasting and nonfasting healthy men. Antimicrob Agents Chemother 48:804–808

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  176. Ezzet F, Wexler D, Courtney R et al (2005) Oral bioavailability of posaconazole in fasted healthy subjects comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 44:211–220

    Article  PubMed  CAS  Google Scholar 

  177. Krishna G, Sansone-Parsons A, Martinho M et al (2007) Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 51:812–818

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  178. Krieter P, Flannery B, Musick T et al (2004) Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 48:3543–3551

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  179. Raad II, Graybill JR, Bustamante AB et al (2006) Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 42:1726–1734

    Article  PubMed  CAS  Google Scholar 

  180. Kurtz MB, Rex JH (2001) Glucan synthase inhibitors as antifungal agents. Adv Protein Chem 56:463–475

    Google Scholar 

  181. Feldmesser M, Kress Y, Mednick A et al (2000) The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis 182:1791–1795

    Article  PubMed  CAS  Google Scholar 

  182. Espinel-Ingroff A (1998) Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 36:2950–2956

    PubMed Central  PubMed  CAS  Google Scholar 

  183. Denning DW (2002) Echinocandins: a new class of antifungals. J Antimicrob Chemother 49:889–891

    Article  PubMed  CAS  Google Scholar 

  184. Balani SK, Xu X, Arison BH et al (2000) Metabolites of caspofungin acetate, a potent antifungal agent in human plasma and urine. Drug Metab Dispos 28:1274–1278

    PubMed  CAS  Google Scholar 

  185. Hebert MF, Smith HE, Marbury TC et al (2005) Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 45:1145–1152

    Article  PubMed  CAS  Google Scholar 

  186. Stogniew M, Pu F, Henkel T et al (2003) Anidulafungin biotransformation in humans is by degradation not metabolism. Clin Microbiol Infect 9:291

    Google Scholar 

  187. Stone JA, Migoya EM, Hickey L et al (2004) Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 48:4306–4314

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  188. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M et al (2004) Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 34:13–20

    Article  PubMed  CAS  Google Scholar 

  189. Hebert MF, Townsend RW, Austin S et al (2005) Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 45:954–960

    Article  PubMed  CAS  Google Scholar 

  190. Greer N (2008) Doripenem (Doribax): the newest addition to the carbapenems. Proc (Bayl Univ Med Cent). 21(3):337–341

    Google Scholar 

  191. Tenover FC, Moellering RC Jr (2007) The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 44:1208–1215

    Article  PubMed  CAS  Google Scholar 

  192. Rubinstein E, Cammarata S, Oliphant T, Wunderink R, Linezolid Nosocomial Pneumonia Study Group (2001) Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double blind, multicenter study. Clin Infect Dis 32:402–412

    Article  PubMed  CAS  Google Scholar 

  193. Bellmann R, Egger P, Wiedemann CJ et al (2003) Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence. Clin Infect Dis 36:1500–1501

    Article  PubMed  CAS  Google Scholar 

  194. Cornely OA, Maertens J, Bresnik M et al (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (Ambiload trial). Clin Infect Dis 44:1289–1297

    Article  PubMed  CAS  Google Scholar 

  195. Thomas LD, Miller GG, The AST Infectious Diseases Community of Practice (2009) Interactions between antiinfective agents and immunosuppressants. Am J Transplant 9(Suppl4):263–266

    Article  Google Scholar 

  196. Boogaerts MA, Maertens J, Van Der Geest R et al. (2001) Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob Agents Chemoter 45:981–985

    Google Scholar 

Download references

Acknowledgments

The authors thank Yi Guo, PharmD for assistance in outline of this chapter.

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Montefiore Medical Center, 111 E. 210th Street, Bronx, NY, 10467-2790, USA

    Ximena Millan, Victoria Muggia & Belinda Ostrowsky

Authors
  1. Ximena Millan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victoria Muggia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Belinda Ostrowsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Belinda Ostrowsky .

Editor information

Editors and Affiliations

  1. Div. Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

    Valentina Stosor

  2. Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

    Teresa R. Zembower

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Millan, X., Muggia, V., Ostrowsky, B. (2014). Antimicrobial Agents, Drug Adverse Reactions and Interactions, and Cancer. In: Stosor, V., Zembower, T. (eds) Infectious Complications in Cancer Patients. Cancer Treatment and Research, vol 161. Springer, Cham. https://doi.org/10.1007/978-3-319-04220-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-04220-6_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-04219-0

  • Online ISBN: 978-3-319-04220-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation